Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier

Executive Summary

Perrigo concealed problems related to its 2015 acquisition of Omega and over-inflated the firm’s resistance to generic drug pricing pressures in its defense against Mylan's tender, shareholder group Carmignac Gestion says in a lawsuit.

You may also be interested in...



Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount

Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.

Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount

Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.

Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth

Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel